Journals / Medeniyet Medical Journal / 2018 / Cilt: 33 - Sayı: 1

Comparison of the effects of corticosteroid therapy on pulmonary and extrapulmonary ARDS patients

Pulmoner ve extrapulmoner kaynaklı ARDS hastalarında kortikosteroid tedavisinin etkilerinin karşılaştırılması

Pages
41–46
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, although previous studies have shown an increased survival rate in ARDS patients who received methylprednisolone therapy, in our study it was found that survival rate was lower in extrapulmonary ARDS compared to pulmonary ARDS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Previous studies have shown that low-dose and long-term corticosteroid therapy is associated with good clinical outcomes in patients with acute respiratory distress syndrome (ARDS).
📊
Key Findings & Data:The data of 22 patients, who were followed up in intensive care unit, diagnosed as ARDS and underwent low-dose and long-term methylprednisolone treatment between January 2008 and December 2012 were retrospectively investigated.
💡
Conclusion & Impact:In conclusion, although previous studies have shown an increased survival rate in ARDS patients who received methylprednisolone therapy, in our study it was found that survival rate was lower in extrapulmonary ARDS compared to pulmonary ARDS.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Previous studies have shown that low-dose and long-term corticosteroid therapy is associated with good clinical outcomes in patients with acute respiratory distress syndrome (ARDS). However, there is no study investigating the efficacy of corticosteroids in these patients according to ARDS types. The aim of our study is to compare the clinical parameters and in-hospital outcomes of pulmonary and extrapulmonary ARDS patients who were treated with corticosteroids in addition to conventional treatments. The data of 22 patients, who were followed up in intensive care unit, diagnosed as ARDS and underwent low-dose and long-term methylprednisolone treatment between January 2008 and December 2012 were retrospectively investigated. Patients were divided into two main groups as pulmonary ARDS (14 patients) and extrapulmonary ARDS (8 patients), and comparisons were made. There was no significant difference between pulmonary ARDS and extrapulmonary ARDS groups in terms of age, gender, weight, length of stay in intensive care unit, onset day of ARDS development, and duration of mechanical ventilation (MV). However, the weaning from MV and in-hospital survival rate was significantly lower in extrapulmonary ARDS group. In multivariate analysis, extrapulmonary ARDS was detected as an independent predictor of in-hospital mortality. In conclusion, although previous studies have shown an increased survival rate in ARDS patients who received methylprednisolone therapy, in our study it was found that survival rate was lower in extrapulmonary ARDS compared to pulmonary ARDS. Therefore, it is concluded that more detailed studies are required to demonstrate the benefit of corticosteroids in the treatment of extrapulmonary cases of ARDS.

Özet

Daha önceki çalışmalarda, düşük doz ve uzun süreli kortikosteroid tedavisinin akut solunum sıkıntısı sendromlu (ARDS) hastalarda iyi klinik sonlanımlar ile ilişkili olduğu gösterilmiştir. Ancak, bu hastalarda ARDS tiplerine göre kortikosteroidlerin etkinliğini inceleyen bir çalışma bulunmamaktadır. Çalışmamızın amacı, konvansiyonel tedavilere ek olarak kortikosteroid tedavisi uygulanan pulmoner ve ekstrapulmoner kaynaklı ARDS hastalarının, klinik parametreleri ve hastane içi sonlanımlarını karşılaştırmaktır. Ocak 2008 - Aralık 2012 tarihleri arasında yoğun bakım ünitesinde takip edilen, ARDS tanısı alan ve düşük doz-uzun süreli metilprednizolon tedavisi uygulanan 22 hastanın verileri geriye dönük olarak incelendi. Hastalar, pulmoner kaynaklı ARDS (14 hasta) ve ekstrapulmoner kaynaklı ARDS (8 hasta) olarak iki ana guruba ayrıldı ve karşılaştırmalar yapıldı. Tüm hastalara konvansiyonel tedavilere ek olarak metilprednizolon tedavisi uygulandı. Pulmoner ARDS ve ekstrapulmoner ARDS grupları arasında yaş, cinsiyet, ağırlık, yoğun bakımda kalış süresi, ARDS gelişen gün ve mekanik ventilatörde (MV) kalma süresi açısından anlamlı bir farklılık belirlenmedi. Ancak, ekstrapulmoner kaynaklı ARDS grubunda MV’den ayrılma oranı ve hastane içi sağkalım oranı anlamlı olarak daha az idi. Çok değişkenli analizde, ekstrapulmoner kaynaklı ARDS hastane içi ölümün bağımsız öngördürücüsü olarak belirlendi. Sonuç olarak, önceki çalışmalarda metilprednizolon tedavisi uygulanan ARDS hastalarında sağkalım oranının artmış olduğu gösterilmiş olmasına rağmen, çalışmamızda extrapulmoner kaynaklı olgularda sağkalım oranının pulmoner kaynaklı olgulara oranla daha düşük olduğu gözlendi. Bu nedenle ekstrapulmoner kaynaklı ARDS olgularında kortikosteroidlerin faydasını göstermek için daha kapsamlı çalışmalara gereksinim olduğu sonucuna varıldı.

🔖

Cite This Article

TANRIVERDİ, T. B., KOLTKA, E. N., ÖZCAN, H. G., ERDEM, E., ÇELİK, M. G. (2018). Comparison of the effects of corticosteroid therapy on pulmonary and extrapulmonary ARDS patients. Medeniyet Medical Journal, Cilt: 33 - Sayı: 1, 41–46. https://ajindex.com/articles/283417

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Özyurt Y, Erkal H, Demirhan R, et al. Akut respiratuar distres sendromu. Türk Gögüs Kalp Damar. 2002;10:126-30.
  2. Ragaller M, Richter T. Acute lung injury and acute respiratory distress syndrome. J Emerg Trauma Shock. 2010;3:43-51. https://doi.org/10.4103/0974-2700.58663
  3. Bernard GR, Artigas A, Brigham KL, et al. The AmericanEuropean Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-24. https://doi.org/10.1164/ajrccm.149.3.7509706
  4. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-49. https://doi.org/10.1056/NEJM200005043421806
  5. Pelosi P, D’Onofrio D, Chiumello D, et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J Suppl. 2003;42:48s-56s. https://doi.org/10.1183/09031936.03.00420803
  6. Altıntaş ND, İskit AT. Akut solunum sıkıntısı sendromu tanısı ve tedavisinde güncel yaklaşımlar. Tüberküloz ve Toraks Dergisi. 2009;57:228-36.
  7. Crimi E, Slutsky AS. Inflammation and the acute respiratory distress syndrome. Best Pract Res Clin Anaesthesiol. 2004;18:477-92. https://doi.org/10.1016/j.bpa.2003.12.007
  8. Jain R, DalNogare A. Pharmacological therapy for acute respiratory distress syndrome. Mayo Clin Proc. 2006;81:205-12. https://doi.org/10.4065/81.2.205
  9. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993;14:436-41. https://doi.org/10.1016/0165-6147(93)90184-L
  10. Khilnani GC, Hadda V. Corticosteroids and ARDS: A review of treatment and prevention evidence. Lung India. 2011;28:114-9. https://doi.org/10.4103/0970-2113.80324
  11. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954-63. https://doi.org/10.1378/chest.06-2100
  12. Weigelt JA, Norcross JF, Borman KR, et al. Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536-40. https://doi.org/10.1001/archsurg.1985.01390290018003
  13. Bone RC, Fisher CJ, Jr, Clemmer TP, et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92:1032-6. https://doi.org/10.1378/chest.92.6.1032
  14. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62-8. https://doi.org/10.1164/ajrccm/138.1.62 Meduri GU,